BioSpace News Archive

PDI, a global leader in infection prevention product and service solutions, today announced the appointment of Michael Yang, Ph.D., as Senior Vice President of Research and Development (R&D).

Genosity, Inc., an innovative biotechnology company that provides comprehensive software and technical solutions to enable precision medicine announced today that it has entered into a strategic collaboration with Personal Genome Diagnostics Inc. (PGDx), one of the leading companies in cancer genomics, that recently received market clearance from the U.S. Food and Drug Administration (FDA) for PGDx elio™ tissue complete

Newswire’s Earned Media Advantage Guided Tour Market Builder presents a major opportunity for medical manufacturers, medical tech firms, and healthcare leaders heading into the winter season.

- On September 11, 2020, Health Canada approved Trulicity® (dulaglutide) to reduce the risk of non-fatal stroke in adults with type 2 diabetes mellitus who have multiple cardiovascular risk factors or established cardiovascular disease, as an adjunct to diet, exercise, and standard of care therapy. This decision makes Eli Lilly and Company’s Trulicity the first and only GLP1 receptor agonist (RA) approved to provide a cardiovascular benefit in people w

The International Respiratory Infections Society (IRIS) is pleased to announce the release of an industry-first, a comprehensive How-To Manual for Drive-Through Vaccination Clinics

Company pursuing additional application for JAN101 to treat COVID-19 complications Stable formulation and engineering for JAN101 will support Phase 2b PAD Study under the FDA’s Investigational New Drug (IND) #111703, expected to begin the first quarter of 2021 Scientific Advisory Board bolstered by expert additions [22-September-2020] LAS VEGAS , Se

NeuroTherapia, Inc., a clinical-stage company focused on developing therapies for neurodegenerative diseases, announced today the closing of its Series A financing of $8.8M . The Series A round, led b

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into a collaboration with Dana-Farber Cancer Institute (DFCI) in the United States, to investigate the use of Kazia’s investigational new drug, paxalisib (formerly GDC-0084

symplr, a leading global healthcare governance, risk, and compliance (“GRC”) software-as-a-service (“SaaS”) platform, backed by Clearlake Capital Group, L.P. (together with its affiliates, “Clearlake”) and SkyKnight Capital (together with its affiliates, “SkyKnight”), has completed its acquisition of ComplyTrack® from Wolters Kluwer.

ECRI recommends that non-certified KN95 masks from China be reserved by healthcare institutions for use in non-COVID-19 circumstances